19 Mar 2020: IXICO PLC's (LON:IXI) chief business officer Lammert Albers talks Proactive's Andrew Scott through an extended contract they've secured with Vaccinex Inc (NASDAQ:VCNX).
It's to provide services on a trial of a potential treatment for Alzheimer’s disease.
The company’s digital platform and artificial intelligence (AI) software manages and helps interpret images from magnetic resonance imaging (MRI) and other scanners.
11 Mar 2020: IXICO PLC's (LON:IXI) CEO Giulio Cerroni and CFO Grant Nash presenting at Shares Investor Evenings in London
7 Feb 2020: IXICO PLC's (LON:IXI) Chief Product Officer Alison Howie tells Proactive London's Andrew Scott they're to provide funding and expertise for the Alzheimer's Disease Neuroimaging Initiative (ADNI).
Two of IXICO's scientists will join the private partner scientific board of ADNI which is looking to develop clinical, imaging, genetic and biochemical biomarkers for the early detection and tracking of Alzheimer's disease.
4 Dec 2019: IXICO PLC's (LON:IXI) CEO Giulio Cerroni sat down with Proactive London's Andrew Scott after reporting its first year of profitability since its admission to AIM.
For the year ended 30 September, the neuroscience analytics firm swung to an underlying (EBITDA) profit of £500,000 from a £600,000 loss in the prior year, while revenues rose 40% to a record level of £7.6mln.
7 Nov 2019: Lammert Albers sits down with Proactive London's Andrew Scott soon after his appointment as IXICO PLC’s (LON:IXI) chief business officer.
With expertise of the Alzheimer's disease trials market he says he'll be responsible for executing the company's global business development strategy in both existing and new markets.
15 Oct 2019: IXICO PLC's (LON:IXI) Giulio Cerroni tells Proactive London's Andrew Scott they'll post the firm's first annual underlying profit since it listed after revenues in its latest year surged 40%.
He says the performance is better than expected as sales growth had accelerated since the half-year.
23 Aug 2019: IXICO PLC (LON:IXI) CFO Grant Nash says the firm's performance for the current year will be materially ahead of market expectations - benefitting from new and expanded contracts, the deployment of newly-developed algorithms and faster turnaround times in trial initiation.
Nash, who was appointed to the role in April, has this week joined the board with immediate effect.
14 Aug 2019: IXICO PLC's (LON:IXI) Chief Commercial Officer Alison Howie tells Proactive London's Andrew Scott they've secured two new client contracts with a combined value of over £1mln.
She adds there's also been a significant change order that expands its involvement in a phase III clinical trial for Huntington's disease worth an additional £900,000.
22 May 2019: IXICO PLC's (LON:IXI) CEO Giulio Cerroni talks Proactive London's Andrew Scott through the neuroscience-focused data analytics group's results for the six months to the end of March 2019.
The firm reported a pre-tax profit on ordinary activities of £106,000, up from a £514,000 loss in the prior year, while revenues jumped to £3.4mln from £2.8mln. Gross margins also rose by 610 basis points to 66.3%
25 Apr 2019: Giulio Cerroni, chief executive of IXICO PLC (LON:IXI), caught up with Proactive London's Andrew Scott to talk through their trading update for the six months to 31 March.
Revenues at the neuroscience-focused data analytics group for the period are expected to be £3.43mln, 22% higher than a year ago, while its cash balance is £7.5mln compared to £2.7mln previously.
24 Apr 2019: IXICO PLC's (LON:IXI) John Hall came into Proactive London to discuss two significant new contracts they've agreed with new biopharmaceutical clients.
The first contract, to support an early phase study into Huntington’s Disease (HD), is worth around £2mln and will be delivered over seven years.
The other's for a Phase 3 study for another rare neurological disease.
5 Mar 2019: IXICO PLC's (LON:IXI) senior vice president of corporate development John Hall speaks to Proactive London after announcing that they're to provide data analytics and neuroimaging services to a late-stage programme for people with the degenerative brain disorder Huntington's disease.
IXICO’s involvement will generate a further £500,000 in revenues.
4 Dec 2018: Giulio Cerroni, chief executive of IXICO PLC (LON:IXI), caught up with Proactive London’s Andrew Scott to discuss their results for the year to the end of September as well as the expansion to a contract.
The scope of a current contract with a top 10 biopharmaceutical company has been enlarged, increasing the value by US$2.4mln over the remaining six-year term of the agreement to US$5.1mln.
Where IXICO’s results are concerned revenue rose 32% to £5.39mln from £4.10mln the year before, while the gross margin improved to 58.8% from 56.4%.
The loss before tax narrowed to £793,000 from £1.91mln the previous year.
21 Aug 18: Giulio Cerroni, Chief Executive Officer of IXICO, said:
“Performance for the current financial year is now expected to be “ahead of market expectations”. Reported revenue for the full year is expected to be at least £5.1mln, a 24% increase on the previous year.”
23 May 2018: Giulio Cerroni, Chief Executive Officer of IXICO, said:
“The company is seeing topline growth of 30% in a strong set of interim results. The company is also seeing improvements in its gross margins and cash position. He adds that the company recently raised £5.5mln through an oversubscribed placing, and has brought some new institutional investors on board.”
23 May 2018: IXICO’s leadership team announces strong interim results, outlines its plans for future investment with the proceeds of the recent capital raise, and describes the significance of its recently commercialised digital technology products.
For the full webcast, please visit vimeo.com.
28 Nov 17: Giulio Cerroni, Chief Executive Officer of IXICO, said:
“I have set out a commercially-led growth plan to deliver top-line growth. We will build on IXICO’s trusted position in providing neuroimaging technology enabled specialist services to the biopharmaceutical industry across three key value segments: